An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva [erlotinib] in Combination With Gemcitabine on Disease Progression in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 19 Sep 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 19 Feb 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 Feb 2010 Planned number of patients changed from 12 to 20 as reported by ClinicalTrials.gov.